Astrazeneca Regulatory News (AZN)

29 March 2019

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY JURISDICTION IN WHICH THE SAME WOULD BE UNLAWFUL. THIS ANNOUNCEMENT IS NOT AN OFFER OF SECURITIES IN THE UNITED STATES, CANADA, SOUTH AFRICA, AUSTRALIA, JAPAN OR ANY JURISDICTION IN WHICH THE SAME WOULD BE UNLAWFUL.

Results of Placing

AstraZeneca PLC (the "Company" or "AstraZeneca") is pleased to announce the successful completion of the placing announced earlier today (the "Placing").

A total of 44,386,214 new ordinary shares of twenty-five cents each in the Company (the "Placing Shares") have been placed by Goldman Sachs International ("Goldman Sachs") and Morgan Stanley & Co. International plc ("Morgan Stanley") with both existing and new institutional investors at a price of £60.50 per Placing Share (the "Placing Price"), raising proceeds of approximately £2.69 billion ($3.5 billion at a GBP:USD average exchange rate of 1.3034) (before expenses). The Placing Shares being issued represent approximately 3.5 per cent. of the issued ordinary share capital of the Company.

The Placing Price of £60.50 each represents a discount of 1.5 per cent. to the middle market price at the time at which the Company, Goldman Sachs and Morgan Stanley agreed the Placing Price and complies with the guidance set out in the 'Statement of Principles' in respect of the disapplication of pre-emption rights issued by the Pre-Emption Group in 2015. The Placing Shares, when issued, will be credited as fully paid and will rank pari passu in all respects with the existing ordinary shares of twenty-five cents each in the capital of the Company, including the right to receive all dividends and other distributions declared, made or paid on or in respect of such shares after the date of issue.

Applications have been made for admission of the Placing Shares to the premium listing segment of the Official List of the Financial Conduct Authority (the "Official List") and to trading on the main market of the London Stock Exchange plc (together, "Admission"). It is expected that settlement for the Placing Shares and Admission will take place at 8.00 a.m. on 2 April 2019. Settlement of the Placing is conditional upon, amongst other things, Admission becoming effective and upon the placing agreement not being terminated in accordance with its terms.

Following Admission the total number of shares in issue in the Company will be 1,311,755,099.

END

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com and follow us on Twitter @AstraZeneca.

Important Information:

This announcement and the information contained in it is restricted and is not for release, publication or distribution, directly or indirectly, in whole or in part, in, into or from the United States. This announcement does not contain or constitute an offer or sale or the solicitation of an offer to purchase securities in the United States. The Placing Shares have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration under the Securities Act or an available exemption from, or transaction not subject to, the registration requirements of the Securities Act.

Adrian Kemp

Company Secretary

AstraZeneca PLC